NewTimeSpace News, HENGRUI PHARMA announced on January 26 that it has received the "Drug Clinical Trial Approval Notice" for SHR-1049 Injection issued by the National Medical Products Administration (NMPA), which grants approval for the drug to conduct a single-agent clinical trial for the treatment of advanced solid tumors.
NewTimeSpace News , EMINENCE ENT announced the completion of a placement pursuant to general mandate on January 26. The company issued 115.88 million new shares to six independent third-party placees at HK$0.32 per share, raising a total of HK$37.0816 million. After deducting relevant costs, the net proceeds amount to approximately HK$36.7108 million, which are intended for the refinancing and repayment of existing bank loans.
NewTimeSpace News: Zhaoke Ophthalmology Limited (06622.HK) announced that it has expanded its collaboration agreement with AFT Pharmaceuticals and established a new strategic partnership with Japanese ophthalmology company Santen Pharmaceutical, to advance the commercialization of its core investigational presbyopia treatment drug BRIMOCHOL™ PF in Singapore and Vietnam respectively. The Prescription Drug User Fee Act (PDUFA) date for the drug’s New Drug Application (NDA) in the U.S. is set for January 28, 2026.
FIRST SERVICE announced a change in executive director on January 26. Mr. Jin Chungang resigned from the position due to a shift in work focus and was transferred to Group Deputy General Manager, responsible for the overall operation and management of the company in Northwest China. Mr. Wang Song was appointed as Executive Director with a three-year term.
ASIAINFO TECH disclosed in an announcement on January 26 that it has jointly established the "Embodied Intelligence Lab" with ABB Robotics, with technical support from Alibaba Cloud and NVIDIA. This marks the substantial implementation stage of the strategic cooperation between the two parties in the field of Physical AI (Physical Artificial Intelligence).
B&K listed on 22 December 2025 at HKD 38.20 per share and closed at HKD 10.71 on 23 January 2026, a loss of more than 70%. Marketed as “Hong Kong’s first PDGF stock”, its lead candidates are in Phase II trials, but the company has yet to generate meaningful revenue and remains loss-making.
On January 23rd, CINDA INTL HLDG released a profit warning, projecting a consolidated net profit of approximately HK$74 million to HK$82 million for the 2025 fiscal year. This represents a substantial year-on-year increase of 616% to 703% compared to the HK$10.34 million consolidated after-tax profit attributable to equity holders in 2024. The performance growth is mainly attributed to the reversal of impairment losses, increased exchange gains, and rising bond investment returns.
On January 23rd, Huabao Fragrance Co., Ltd., a subsidiary of HUABAO INTL, further subscribed to principal-guaranteed structured deposits with Bank of Jiangsu. The total outstanding investment amount reached RMB1.2 billion, aiming to activate idle funds and enhance capital returns.
DONGFENG GROUP disclosed on January 23 that the prerequisite conditions for the company's privatization merger have achieved another breakthrough. The company has completed the filing procedure for the introduction of listing with the Department of International Cooperation of the China Securities Regulatory Commission (CSRC). Prior to this, prerequisite conditions such as approvals from the National Development and Reform Commission (NDRC), the Ministry of Commerce, and the approval of Lantu's shareholders have all been fulfilled. Currently, only the in-principle approval from the Hong Kong Stock Exchange (HKEX) remains pending, and the state-owned shareholder identification has been successfully obtained.
Newtrend was listed on the Hong Kong Stock Exchange on June 10, 2025, with an issue price of HKD 18.9 per share. According to the prospectus, the company is a food additive producer, with core products sucralose and food-grade glycine mainly sold overseas. Since its listing, the company's stock price has continuously declined, falling by more than 50% as of January 22, 2026, with an average daily trading volume of less than HKD 100,000.
Unisound AI Technology Co., Ltd. (09678.HK) announced that it has recently signed a cooperation agreement with the People's Government of Guangxi Zhuang Autonomous Region to jointly build the China - ASEAN Countries Artificial Intelligence Application Cooperation Center. This marks the Company's first strategic partnership with a provincial (autonomous regional) - level government. The Company has established a wholly - owned subsidiary in Nanning to serve as its ASEAN headquarters and will expand its business with the "AI + Healthcare" initiative as a breakthrough point.
Karrie International Holdings Limited (01050.HK) released a voluntary announcement disclosing multiple progress milestones in its artificial intelligence (AI) server business. The Group has secured server chassis orders from a leading AI enterprise and entered the mass production phase, while also obtaining the product design for the client’s next-generation AI architecture. In addition, the Group has commenced mass production of ASIC server chassis for a leading U.S. tech enterprise and expects robust capacity demand in 2026.
JNBY Design Limited (03306.HK) announced that the Company has entered into a placing agreement with the placing agent, proposing to place a maximum of 14.535 million new shares at a price of HK$18.78 per share (representing a discount of approximately 9.01% to the previous day's closing price), with an expected net proceeds of approximately HK$270 million. The placing shares will be issued pursuant to the general mandate, without the need for additional shareholder approval.
On January 22, PHARMARON announced the completion of its H-share placement. The company placed 58,440,800 new H-shares to no fewer than six independent placees at a price of HK$22.82 per share, raising net proceeds of approximately HK$1.319 billion. The funds will be used for facility construction, debt repayment, and working capital supplementation. Following the placement, the proportion of H-shares in the company’s total issued share capital has increased to 19.28%.
On January 22, 51WORLD announced that the stabilization period for its global offering has expired on the same day. No stabilization actions were taken during the period, and the over-allotment option has lapsed due to no over-allocation. The company’s public float continues to comply with the requirements of the listing rules.
The Securities and Futures Commission of Hong Kong (SFC) issued an announcement stating that the shareholding of Affluent Foundation Holdings Limited (01757.HK) is highly concentrated in a small number of shareholders. As of January 12, 2026, the company's largest shareholder and another 25 shareholders held a combined shareholding of 90.63%, with only 9.37% of the shares held by other investors. The SFC warned that highly concentrated shareholding may lead to substantial fluctuations in the share price, and investors are advised to exercise extreme caution when trading the shares.
